<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830660</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-TPOP1</org_study_id>
    <nct_id>NCT01830660</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Placebo-controlled, Ascending Single And Multiple Oral Dose Study To Investigate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Hetrombopag Olamine (SHR8735 Olamine) In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hetrombopag Olamine made by Jiangsu Hengrui Medicine co Ltd. has shown an effect of
      increasing platelet count in animal and human. This study is designed in dose escalation
      fashion to evaluate safety, pharmacokinetics and efficacy of Hetrombopag Olamine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate safety and tolerability of Hetrombopag Olamine.

        2. To investigate pharmacokinetics of Hetrombopag Olamine Under fasting conditions.

        3. To obtain pharmacodynamics information of Hetrombopag Olamine on platelet count
           elevation in healthy volunteers.

        4. To determine preliminary regimen for phase II study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in platelet count above baseline(%)on Day1,3,5,8,10,12,15,17,19,22,25,28 after dosing</measure>
    <time_frame>up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite pharmacokinetic (PK) parameters of eltrombopag following a single dose of eltrombopag</measure>
    <time_frame>For 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical laboratory parameters</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>hetrombopag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine Tablets</intervention_name>
    <arm_group_label>hetrombopag</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be adequately informed of the nature and risks of the study, able to
             understand the risks associated with the study, and are willing to provide written
             informed consent prior to screening.

          2. Must be a healthy male between the ages of 18 to 45 years, inclusive.

          3. Must have a BMI between 19 to 28 kg/m2, inclusive and a total body weight â‰¥50 kg.

          4. Platelet counts must be within the normal range.

          5. Subjects must be free of any clinically significant disease based on medical history
             and physical examination.

          6. Clinical laboratory tests (complete blood count [CBC], blood chemistries, and
             urinalysis) must be within the normal limits or clinically acceptable.

          7. Must be nonsmokers, defined as not having smoked tobacco or used chewing tobacco or
             nicotine.

          8. Subjects of reproductive potential with partners who are women of childbearing
             potential, will be instructed to, and must be willing to practice a highly effective
             method of birth control for the duration of the study and continuing 6 months after
             discontinuing treatment with the investigational product.

        Exclusion Criteria:

          1. History of hypersensitivity to hetrombopag olamine or its components.

          2. History or presence of significant cardiovascular deficient, pulmonary, hepatic,
             gallbladder or biliary tract, renal, hematological, gastrointestinal, endocrine,
             immunological, dermatological, neurological, or psychiatric disease, or any other
             condition known to interfere with the absorption, distribution, metabolism, or
             excretion of drugs.

          3. History of deep vein thrombosis, or any other thromboembolic event.

          4. History or presence of conditions that may place the subject at increased risk as
             determined by the investigator.

          5. History of thrombocytopenia or bleeding due to abnormal platelet number or function.

          6. History of platelet clumping that prevents reliable measurement of platelet counts.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maozhi Liang, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <last_update_submitted>April 3, 2015</last_update_submitted>
  <last_update_submitted_qc>April 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

